BDMD logo

Baird Medical Investment Holdings Limited (BDMD) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Baird Medical Investment Holdings Limited (BDMD) opera en el sector Healthcare, cotizado por última vez a $2.03 con una capitalización de mercado de 75M. La acción obtiene una puntuación de 53/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 9 feb 2026
Puntuación de IA de 53/100 MCap 75M Vol 358K

Baird Medical Investment Holdings Limited (BDMD) Resumen de Asistencia Médica y Tuberías

CEOHaimei Wu
Empleados148
Sede CentralGuangzhou, CN
Año de la oferta pública inicial (OPI)2021

Baird Medical Investment Holdings Limited pioneers minimally invasive tumor treatment in China with innovative microwave ablation technology, targeting a significant market opportunity in benign and malignant tumor therapy, but faces challenges in profitability and market penetration given its negative P/E ratio of -7.66 and small market cap of $0.03B.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 9 feb 2026

Tesis de Inversión

Investing in Baird Medical presents a high-risk, high-reward opportunity. The company's focus on minimally invasive tumor treatment aligns with a growing trend in healthcare, potentially driving demand for its microwave ablation devices. The high gross margin of 86.9% indicates strong pricing power and efficient production. However, the negative P/E ratio of -7.66 and small market capitalization of $0.03B highlight significant financial challenges. Key to the investment thesis is Baird Medical's ability to achieve profitability and scale its operations within the Chinese market. Upcoming regulatory approvals and successful market penetration could serve as major catalysts. Investors should closely monitor the company's financial performance and progress in expanding its market share.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • High Gross Margin: Baird Medical boasts a gross margin of 86.9%, indicating efficient production and strong pricing power.
  • Minimally Invasive Focus: The company specializes in microwave ablation, a growing trend in tumor treatment.
  • Chinese Market Focus: Baird Medical targets the large and growing Chinese market for medical devices.
  • Negative P/E Ratio: The company has a P/E ratio of -7.66, reflecting current unprofitability.
  • Small Market Cap: With a market capitalization of $0.03B, Baird Medical is a micro-cap company with associated risks and potential for high growth.

Competidores y Pares

Fortalezas

  • Specialized in microwave ablation technology
  • Focus on minimally invasive tumor treatment
  • Established presence in the Chinese market
  • High gross margin (86.9%)

Debilidades

  • Small market capitalization ($0.03B)
  • Negative P/E ratio (-7.66) indicating unprofitability
  • Limited geographic reach (primarily China)
  • Dependence on regulatory approvals

Catalizadores

  • Upcoming: Regulatory approvals for new microwave ablation devices.
  • Ongoing: Expansion of sales and distribution network in China.
  • Ongoing: Strategic partnerships with hospitals and research institutions.
  • Ongoing: Increasing awareness and adoption of minimally invasive tumor treatment.

Riesgos

  • Potential: Failure to obtain regulatory approvals for new products.
  • Ongoing: Intense competition from established medical device companies.
  • Potential: Economic downturn in China impacting healthcare spending.
  • Ongoing: Dependence on a single geographic market (China).
  • Potential: Product liability claims.

Oportunidades de crecimiento

  • Market Penetration in China: The Chinese market for minimally invasive tumor treatment is vast and growing. Baird Medical has the opportunity to expand its market share by increasing its sales and distribution network, targeting hospitals and clinics across China. Successful penetration could significantly boost revenue and profitability. Timeline: Ongoing.
  • Expansion of Product Portfolio: Baird Medical can develop new microwave ablation devices for treating a wider range of tumors and conditions. This could involve investing in research and development to create innovative products that address unmet medical needs. A broader product portfolio would enhance the company's competitive position. Timeline: 2-3 years.
  • International Expansion: While currently focused on China, Baird Medical could explore opportunities to expand into other international markets. This would require adapting its products to meet local regulatory requirements and establishing partnerships with distributors in new regions. International expansion could diversify revenue streams and reduce reliance on the Chinese market. Timeline: 3-5 years.
  • Strategic Partnerships: Collaborating with hospitals, research institutions, and other medical device companies could accelerate Baird Medical's growth. Partnerships could provide access to new technologies, markets, and distribution channels. Strategic alliances could also enhance the company's credibility and reputation. Timeline: Ongoing.
  • Regulatory Approvals: Obtaining regulatory approvals for its existing and new products is crucial for Baird Medical's growth. Successful navigation of the regulatory landscape will allow the company to commercialize its products and generate revenue. Streamlined regulatory processes and favorable government policies could accelerate this process. Timeline: Ongoing.

Oportunidades

  • Expansion into new geographic markets
  • Development of new microwave ablation devices
  • Strategic partnerships with hospitals and research institutions
  • Increasing demand for minimally invasive procedures

Amenazas

  • Competition from larger medical device companies
  • Regulatory hurdles and delays
  • Economic slowdown in China
  • Technological advancements that could render existing products obsolete

Ventajas competitivas

  • Proprietary microwave ablation technology
  • Established presence in the Chinese market
  • Specialized expertise in minimally invasive tumor treatment
  • Strong relationships with hospitals and clinics in China

Acerca de BDMD

Founded in 2012 and headquartered in Guangzhou, China, Baird Medical Investment Holdings Limited is dedicated to the development and commercialization of microwave ablation medical devices. These devices offer a minimally invasive approach to treating various types of tumors, both benign and malignant. The company's product portfolio is designed to address conditions such as thyroid nodules, liver cancer, lung cancer, and breast lumps, providing an alternative to traditional surgical methods. Baird Medical focuses on the Chinese market, aiming to meet the growing demand for advanced medical technologies in tumor treatment. By offering minimally invasive solutions, Baird Medical seeks to reduce patient trauma, shorten recovery times, and improve overall treatment outcomes. The company operates with a team of 148 employees, focusing on innovation and market expansion within the competitive medical device landscape. Despite a high gross margin of 86.9%, Baird Medical currently faces profitability challenges, reflected in its negative profit margin of -10.0%.

Qué hacen

  • Develops microwave ablation medical devices.
  • Sells microwave ablation medical devices.
  • Focuses on minimally invasive tumor treatment.
  • Targets benign and malignant tumors.
  • Treats thyroid nodules, liver cancer, lung cancer, and breast lumps.
  • Offers an alternative to traditional surgical methods.

Modelo de Negocio

  • Develops and manufactures microwave ablation devices.
  • Sells devices directly to hospitals and clinics.
  • Generates revenue from device sales.
  • Provides training and support to medical professionals.

Contexto de la Industria

Baird Medical operates within the medical device industry, specifically focusing on the market for minimally invasive tumor treatment. This market is experiencing growth driven by technological advancements and patient preference for less invasive procedures. The competitive landscape includes both domestic Chinese companies and international players. Competitors such as BDSX, BEAT, CTSO, ECOR, and FGEN also operate in the broader medical device space, though not all focus specifically on microwave ablation. Baird Medical's success depends on its ability to differentiate its technology, navigate regulatory hurdles, and establish a strong market presence in China.

Clientes Clave

  • Hospitals in China
  • Clinics in China
  • Medical professionals specializing in oncology
  • Patients seeking minimally invasive tumor treatment
Confianza de la IA: 71% Actualizado: 9 feb 2026

Finanzas

Gráfico e información

Precio de la acción de Baird Medical Investment Holdings Limited (BDMD): $2.03 (-0.18, -8.14%)

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BDMD.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para BDMD.

MoonshotScore

53/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de BDMD en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Lo Que los Inversores Preguntan Sobre Baird Medical Investment Holdings Limited (BDMD)

¿Cuáles son los factores clave para evaluar BDMD?

Baird Medical Investment Holdings Limited (BDMD) actualmente tiene una puntuación IA de 53/100, indicando puntuación moderada. Fortaleza clave: Specialized in microwave ablation technology. Riesgo principal a monitorear: Potential: Failure to obtain regulatory approvals for new products.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de BDMD?

BDMD actualmente puntúa 53/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de BDMD?

Los precios de BDMD se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre BDMD?

La cobertura de analistas para BDMD incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en BDMD?

Las categorías de riesgo para BDMD incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to obtain regulatory approvals for new products.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de BDMD?

La relación P/E para BDMD compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está BDMD sobrevalorada o infravalorada?

Determinar si Baird Medical Investment Holdings Limited (BDMD) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de BDMD?

Baird Medical Investment Holdings Limited (BDMD) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available data and may be subject to change.
  • The company's financial performance is volatile and subject to market conditions.
Fuentes de datos

Popular Stocks